Business Context and Reporting Period
Company: GRI Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2024
Event: Commencement of a best efforts public offering (the "Offering") and entry into a Material Definitive Agreement (Securities Purchase Agreement).
Key Financial Metrics and Offering Details
This filing details a capital raise rather than operational financial results. Key metrics include:
- Net Proceeds: Approximately $3.2 million (excluding proceeds from future warrant exercises).
- Securities Issued:
- 60,000 shares of Common Stock.
- 2,125,793 Pre-Funded Warrants (exercise price $0.0001).
- 2,185,793 Series C-1 Warrants (exercise price $1.83; 5-year term).
- 2,185,793 Series C-2 Warrants (exercise price $1.83; 18-month term).
- Offering Price: $1.83 per Share (with warrants); $1.8299 per Pre-Funded Warrant (with warrants).
- Placement Agent Fees: 7.0% cash fee, 1.0% management fee, $25,000 expense allowance, up to $100,000 legal reimbursement, and up to $15,950 clearing expenses.
- Placement Agent Warrants: 153,006 warrants issued to H.C. Wainwright & Co., LLC (exercise price $2.2875).
- Projected Stockholders' Equity: At least $2.5 million post-closing (to meet Nasdaq Rule 5550(b)(1)).
Material Changes and Covenants
The filing outlines significant covenants restricting future capital actions:
- Lock-up Period: The Company agreed not to issue or announce the issuance of Common Stock or convertible securities for 60 days after the closing date.
- Variable Rate Restriction: The Company agreed not to enter into variable rate transactions for one year from the closing date.
- Ownership Caps: Warrant exercise is restricted if the holder would beneficially own more than 4.99% or 9.99% of outstanding shares post-exercise.
Outlook, Management Commentary, and Risks
- Use of Proceeds: Working capital, product candidate development, and general corporate purposes (including public company costs).
- Closing Date: Anticipated on or about June 28, 2024.
- Regulatory Status: The Registration Statement (Form S-1) was declared effective by the SEC on June 26, 2024.
- Risk Factors: The filing notes that representations and warranties are limited to the specific parties and dates of the agreement. Dilution is a material factor due to the issuance of shares and warrants.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds received (filing states "approximately" $3.2 million).
- Confirm the status of the "Warrant Stockholder Approval" required to exercise the Series C-1 and C-2 Warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination provisions and indemnification details.
- Monitor the Company's stockholders' equity to ensure continued compliance with Nasdaq Listing Rule 5550(b)(1).
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants, which are exercisable immediately.